Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360606182> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4360606182 abstract "You have accessJournal of UrologyCME1 Apr 2023MP22-18 A CONTEMPORARY ANALYSIS OF TREATMENT OF MUSCLE INVASIVE BLADDER CANCER USING THE NATIONAL CANCER DATABASE: FACTORS ASSOCIATED WITH RECEIPT OF NON-AGGRESSIVE THERAPY Sol Moon, Vishruti Pandya, Andrew McDonald, Arnab Basu, Sejong Bae, and James Ferguson Sol MoonSol Moon More articles by this author , Vishruti PandyaVishruti Pandya More articles by this author , Andrew McDonaldAndrew McDonald More articles by this author , Arnab BasuArnab Basu More articles by this author , Sejong BaeSejong Bae More articles by this author , and James FergusonJames Ferguson More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003247.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with muscle-invasive bladder cancer (MIBC) face a potentially lethal disease, yet often do not receive potentially curative therapies. This study aims to characterize the treatments received by patients with MIBC, analyze their use according to sociodemographic, clinical, pathologic, and facility measures, and to identify possibilities for improvement in care for patients with MIBC METHODS: Using the NCDB, we analyzed 102,119 patients with non-metastatic muscle invasive bladder cancer diagnosed between 2009-2018. Treatments included cystectomy, radiation, chemotherapy, or observation. Treatments which included cystectomy or radiotherapy >50 Gy were considered aggressive therapy (AT). A multivariable generalized estimating equation model was used to assess the relationship of the independent variables with receiving AT. Statistical analysis was conducted using SAS version 9.4. RESULTS: The median age was 73 years, with 72.9% male, 84.3% White, and 7.1% Black. Stage distribution included 59.4% stage II, 23.0% (III), and 17.6% (IV). Overall, 55.2% of patients received AT, while 41.1% did not, with 26.6% receiving observation alone. 45.4% of patients received cystectomy, 9.8% underwent definitive radiotherapy, and 12.8% underwent chemotherapy as primary treatment. Notably, over 30% of patients between ages of 50 and 70 did not receive aggressive therapy (Figure 1). On multivariate analysis, factors associated with lack of aggressive therapy included age >70 (OR <0.79, p<0.0001), Black race (OR 0.70, p<0.0001), Medicaid and underinsured status (OR 0.62, p<0.0001), Charlson score > 2 (OR 00.74, p<0.0001), and low volume (OR 0.72 p<0.0001), non-academic cancer program (OR 0.54, p<0.0001). Utilization of perioperative chemotherapy and chemoradiotherapy increased over time. CONCLUSIONS: Over a third of patients do not receive aggressive therapy for MIBC, with many of these patients seemingly eligible by age and comorbidity status. Prospective studies are needed to determine exactly why these patients do not receive aggressive therapy. A better understanding of patient vs access to care vs provider factors would help to focus efforts to improve care for patients with MIBC. Source of Funding: VA RDA award to JEF © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e304 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sol Moon More articles by this author Vishruti Pandya More articles by this author Andrew McDonald More articles by this author Arnab Basu More articles by this author Sejong Bae More articles by this author James Ferguson More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W4360606182 created "2023-03-24" @default.
- W4360606182 creator A5001717156 @default.
- W4360606182 creator A5004442337 @default.
- W4360606182 creator A5020125488 @default.
- W4360606182 creator A5032032184 @default.
- W4360606182 creator A5046871150 @default.
- W4360606182 creator A5087500247 @default.
- W4360606182 date "2023-04-01" @default.
- W4360606182 modified "2023-09-26" @default.
- W4360606182 title "MP22-18 A CONTEMPORARY ANALYSIS OF TREATMENT OF MUSCLE INVASIVE BLADDER CANCER USING THE NATIONAL CANCER DATABASE: FACTORS ASSOCIATED WITH RECEIPT OF NON-AGGRESSIVE THERAPY" @default.
- W4360606182 doi "https://doi.org/10.1097/ju.0000000000003247.18" @default.
- W4360606182 hasPublicationYear "2023" @default.
- W4360606182 type Work @default.
- W4360606182 citedByCount "0" @default.
- W4360606182 crossrefType "journal-article" @default.
- W4360606182 hasAuthorship W4360606182A5001717156 @default.
- W4360606182 hasAuthorship W4360606182A5004442337 @default.
- W4360606182 hasAuthorship W4360606182A5020125488 @default.
- W4360606182 hasAuthorship W4360606182A5032032184 @default.
- W4360606182 hasAuthorship W4360606182A5046871150 @default.
- W4360606182 hasAuthorship W4360606182A5087500247 @default.
- W4360606182 hasConcept C121608353 @default.
- W4360606182 hasConcept C126322002 @default.
- W4360606182 hasConcept C136764020 @default.
- W4360606182 hasConcept C2775910329 @default.
- W4360606182 hasConcept C2778979077 @default.
- W4360606182 hasConcept C2780352672 @default.
- W4360606182 hasConcept C41008148 @default.
- W4360606182 hasConcept C509974204 @default.
- W4360606182 hasConcept C71924100 @default.
- W4360606182 hasConcept C77088390 @default.
- W4360606182 hasConceptScore W4360606182C121608353 @default.
- W4360606182 hasConceptScore W4360606182C126322002 @default.
- W4360606182 hasConceptScore W4360606182C136764020 @default.
- W4360606182 hasConceptScore W4360606182C2775910329 @default.
- W4360606182 hasConceptScore W4360606182C2778979077 @default.
- W4360606182 hasConceptScore W4360606182C2780352672 @default.
- W4360606182 hasConceptScore W4360606182C41008148 @default.
- W4360606182 hasConceptScore W4360606182C509974204 @default.
- W4360606182 hasConceptScore W4360606182C71924100 @default.
- W4360606182 hasConceptScore W4360606182C77088390 @default.
- W4360606182 hasIssue "Supplement 4" @default.
- W4360606182 hasLocation W43606061821 @default.
- W4360606182 hasOpenAccess W4360606182 @default.
- W4360606182 hasPrimaryLocation W43606061821 @default.
- W4360606182 hasRelatedWork W1973041883 @default.
- W4360606182 hasRelatedWork W1987212190 @default.
- W4360606182 hasRelatedWork W2028777349 @default.
- W4360606182 hasRelatedWork W2038776230 @default.
- W4360606182 hasRelatedWork W2079205857 @default.
- W4360606182 hasRelatedWork W2164361265 @default.
- W4360606182 hasRelatedWork W2401908859 @default.
- W4360606182 hasRelatedWork W2728560941 @default.
- W4360606182 hasRelatedWork W2993165969 @default.
- W4360606182 hasRelatedWork W3136529388 @default.
- W4360606182 hasVolume "209" @default.
- W4360606182 isParatext "false" @default.
- W4360606182 isRetracted "false" @default.
- W4360606182 workType "article" @default.